

Reference List



Huntington S, McGreevy A, Rebbapragada A, *et al.* First-void urine self-sampling for primary HPV cervical cancer screening: an implementation tool for US healthcare professionals. Poster presented at IPVC Conference; 12-13th November 2024, Edinburgh, UK.

Huntington S, Smith JS, Nuttall D, *et al.* Evidence from Europe on implementation, participation and performance of self-collection for cervical cancer screening. *Future Oncology* 2024 Oct 24, 1–12. DOI: 10.1080/14796694.2024.2409625

Lani E, Polokaova A, Mercer K, *et al.* Understanding the use of mAbs for COVID-19 pre-exposure prophylaxis (PrEP) in patients with haematological malignancies - insights from clinician interviews in Germany. Poster presentation The European Society for Immunodeficiencies (ESID) meeting, 16-19th October 2024, Marseille, France.

d'Arminio Monforte A, d'Ettorre G, Galardo G, *et al.* The potential health economic value of universal opt-out HIV testing in emergency departments in Italy. Oral presentation at Fast-Track Cities 2024; 13-15th October 2024, Paris, France. www.iapac.org/files/2024/10/1335-M-Ruf.pdf

Huntington S, *et al.* Estimating the gap between PrEP use and PrEP need in England. Oral presentation at HIV Prevention England Conference. Prioritising equity and impact. 6th September 2024. London, UK. <https://www.hivpreventionengland.org.uk/2024/09/11/hiv-prevention-england-conference-2024-presentations-and-talks/>

d'Arminio Monforte A, d'Ettorre G, Galardo G, *et al.* OC-4 Estimating the potential health economic value of universal opt-out HIV testing in emergency departments in Italy: a modelling study. *Sexually Transmitted Infections* 100(Suppl 1):A4-A5. DOI: 10.1136/sextrans-ICAR-2024.4. Oral presentation at 16th Italian Conference on AIDS and Antiviral Research, July 2024, Rome, Italy.

Shahaj O, Meiwald A, Puri Sudhir K *et al.* Mapping the Common Barriers to Optimal COPD Care in High and Middle-Income Countries: Qualitative Perspectives from Clinicians. *Int J Chron Obstruct Pulmon Dis.* 2024 May 30; doi: 10.2147/COPD.S449659.

Di Marco, F., Shahaj, O., Valipour, *et al.* Variations in the pharmacological management of COPD due to payer-driven access criteria for triple therapy: Pan-European cross-expertise qualitative insights. 12th International Primary Care Respiratory Group World Conference, 9-11th May 2024, Athens, Greece.

Puri Sudhir K, Kagenaar E, Meijer M *et al.* Comparing the costs and diagnostic outcomes of replacing cytology with the QIASure DNA Methylation Test as a Triage within HPV primary cervical cancer screening in The Netherlands. *Diagnostics.* 2023 Dec 6; 13(24):3612. doi:10.3390/diagnostics13243612

Dombrowski C, Bourgain C, Ma Y, *et al.* An economic evaluation of two cervical screening algorithms in Belgium: HR-HPV primary compared to HR-HPV and liquid-based cytology (LBC) co-testing. *European Journal of Cancer Prevention*. 2023 Nov 6; doi: 10.1097/CEJ.0000000000000856.

Pinsent A, Weston G, Adams EJ, *et al.* Determining the relationship between seizure-free days and other predictors of quality of life in patients with Dravet Syndrome and their carers from FFA registration studies. *Neurol Ther*. 2023 Jun 16; doi: 10.1007/s40120-023-00510-8.

Miners L*, Huntington S*, Lee N *et al.* An economic evaluation of two PCR-based respiratory panel assays for patients admitted to hospital with community-acquired pneumonia (CAP) in the UK, France and Spain. *BMC Pulmonary Medicine*. Available from: <https://doi.org/10.1186/s12890-023-02516-2>

Huntington S, Puri Sudhir K, Schneider V, *et al.* Two self-sampling strategies for HPV primary cervical cancer screening compared with clinician-collected sampling: an economic evaluation. *BMJ Open* 2023;13:e068940. Available from: <http://dx.doi.org/10.1136/bmjopen-2022-068940>

Jameel A, Meiwald A, Bain P, *et al.* The Cost-Effectiveness of unilateral magnetic Resonance-Guided focused ultrasound in comparison to unilateral deep brain stimulation for the treatment of medically refractory essential tremor in England. *BJR*. 2022 Sep 20; 20220137. Available from: <https://doi.org/10.1259/bjr.20220137>

Vankelegom M, Burke D, Mohammed AMF, *et al.* Cost-effectiveness of a rapid point-of-care test for diagnosing patients with suspected bloodstream infection in Ireland. *Informatics in Medicine Unlocked*. 2022 Jan 1; 32:101056. Available from: <https://www.sciencedirect.com/science/article/pii/S2352914822001952>

Dombrowski CA, Weston GM, Descamps PP, *et al.* Health economic evaluation of an mRNA high-risk human papillomavirus (HR-HPV) assay versus a DNA HR-HPV assay for the proposed French cervical screening programme. *Medicine (Baltimore)*. 2022 Jul 22;101(29): e29530.

Meiwald A, Gara-Adams R, Rowlandson A, *et al.* Qualitative Validation of COPD Evidenced Care Pathways in Japan, Canada, England, and Germany: Common Barriers to Optimal COPD Care. *Int J Chron Obstruct Pulmon Dis*. 2022; 17:1507-1521 <https://doi.org/10.2147/COPD.S360983>

Huntington S, Weston G, Adams E. Assessing the clinical impact and resource use of a 30-minute chlamydia and gonorrhoea point-of-care test at three sexual health services. *Therapeutic Advances in Infectious Disease*. January 2021. doi:10.1177/20499361211061645

Gara-Adams R, Mowlem F, Thomas RH, *et al.* Care Pathway Mapping for Dravet Syndrome (DS) Patients in England – interim results from a pilot study. Presented at: ILAE British Branch Virtual Annual Scientific Conference, September 23 – 24, 2021; Virtual

Meiwald A, Gara-Adams R, Ma Y, *et al.* Analysing the COPD care pathway in Japan, Canada, England and Germany: a global view. Presented at: European Respiratory Society International Congress 2021, September 5 – 8, 2021; Virtual

Weston G, Dombrowski C, Steben M, *et al.* A health economic model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada. *Preventive Medicine Reports* [Internet]. 2021 Sep 1; 23:101448. Available from: <https://www.sciencedirect.com/science/article/pii/S2211335521001388>

Pinsent A, Weston G, Adams EJ, *et al.* Determining the Relationship of Seizures, Seizure Free Days and Other Predictors of Health Related Quality of Life in Patients with Dravet Syndrome (DS) and Their Carers. Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 Congress, May 17 - 20, 2021; Virtual

Weston G, Pinsent A, Adams EJ, *et al.* A Cost Effectiveness Analysis of Fenfluramine for the Treatment of Seizures for Patients with Dravet Syndrome (DS) in the UK Setting. Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 Congress, May 17 - 20, 2021; Virtual

Dombrowski C, Weston G, Adams E. Modelling the impact of using a DNA compared to mRNA HPV assay as part of the cervical screening programmes in Sweden and Denmark. Poster presented at: EUROGIN International Multidisciplinary HPV Congress; 2021 May 30 - June 1; Virtual

Dombrowski C, Weston G, Adams E. Evaluating the benefits and costs of using an mRNA versus DNA HR-HPV assay in the National Cervical Screening Programme in the Netherlands. Poster presented at: EUROGIN International Multidisciplinary HPV Congress; 2021 May 30 - June 1; Virtual

Dombrowski C, Weston G, Descamps P, *et al.* Evaluating the choice of HPV assay in the French cervical screening programme with a decision tree model. Poster presented at: EUROGIN International Multidisciplinary HPV Congress; 2021 May 30 - June 1; Virtual

Weston G, Steben M, Popadiuk C, Bentley J, *et al.* Estimating the costs and benefits of HR-HPV assay choice in a theoretical HPV primary cervical screening algorithm in Ontario, Canada. Poster presented at: EUROGIN International Multidisciplinary HPV Congress; 2021 May 30 - June 1; Virtual

Kerry-Barnard S, Huntington, S, Fleming C, *et al.* Near patient chlamydia and gonorrhoea screening and treatment in further education/technical colleges: a cost analysis of the 'Test n Treat' feasibility trial. *BMC Health Services Research* (2020) 20:316 <https://doi.org/10.1186/s12913-020-5062-5>.

Weston G, Dombrowski C, Harvey MJ, *et al.* Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation. *BMJ Open* 2020;10:e031303. doi:10.1136/bmjopen-2019-031303

Micha A, Sinnett V, Wilson R, *et al.* P048. Interim analysis of an evaluation of clinical service impact of switching from wire to magnetic seeds for localisation of impalpable breast lesions for surgery. *Euro J Surg Oncology*, Vol 45, Issue 5, 898. DOI: <https://doi.org/10.1016/j.ejso.2019.01.070>

Micha A, Sinnett V, Wilson R, *et al.* 30. Interim analysis of an evaluation of clinical outcome and patient and clinician satisfaction with magnetic seeds compared with guide wires for localisation of impalpable breast lesions for surgery. *Euro J Surg Oncology*, Volume 45, Issue 5, 884. DOI: <https://doi.org/10.1016/j.ejso.2019.01.216>

Oakeshott P, Kerry-Barnard S, Fleming C, *et al.* "Test n Treat" (TnT): a cluster randomised feasibility trial of on-site rapid Chlamydia trachomatis tests and treatment in ethnically diverse, sexually active teenagers attending technical colleges. *Clin Microbiol & Inf.* Available 1 Nov 2018. doi.org/10.1016/j.cmi.2018.10.019.

Aquarius Population Health, on behalf of the British In Vitro Diagnostics Association (BIVDA) and Innovate UK. Three simple tests could save the NHS at least £6.9 billion. London. June 2018. www.bivda.org.uk/3_simple_tests.pdf

Kerry-Barnard S, Fleming C, Reid F, *et al.* 'Test n Treat (TnT)'- Rapid testing and same-day, on-site treatment to reduce rates of chlamydia in sexually active further education college students: study protocol for a cluster randomised feasibility trial. *Trials*. 2018 Jun 5;19(1):311. doi: 10.1186/s13063-018-2674-8.

Huntington SE, Burns RM, Harding-Esch E, *et al.* Modelling-based evaluation of the costs, benefits and cost-effectiveness of multi-pathogen point-of-care tests for sexually transmitted infections in symptomatic genitourinary medicine clinic attendees. *BMJ Open* 2018;8:e020394. doi: 10.1136/bmjopen-2017-020394

Vecino-Ortiz AI, Goldenberg SD, Douthwaite ST, *et al.* Impact of a multiplex PCR point-of-care test for influenza A/B and respiratory syncytial virus on an acute pediatric hospital ward. *Diag Micro & Infect Dis* 2018. doi.org/10.1016/j.diagmicrobio.2018.03.013

Harvey MJ, Cheng C-Y, Leone E, *et al.* Exploring HCV eradication through diagnosis and treatment strategies. EASL Monothematic Conference, Striving Towards the Elimination of HCV Infection. Berlin, Germany (2018).

Adams EJ, Cheng C-Y, Sacco J, *et al.* Mapping the treatment pathway for metastatic uveal melanoma patients in England: A qualitative pilot study. Society for Immunotherapy of Cancer's 32nd Annual Meeting, Maryland, USA (2017).

Cheng C-Y, Alamgir G, Adams EJ, *et al.* Quantifying standard of care (SOC) hospital-related resource utilisation for metastatic uveal melanoma (MUM) patients in NHS England (NHSE) using the hospital episodes statistics (HES) dataset. *Value in Health* **20**, A514 (2017).

Schwenkglens M, Alamgir G, Cheng, C-Y, *et al.* A real-world evidence (RWE) approach to characterising an ultra-rare disease (URD) cohort of metastatic uveal melanoma (MUM) patients within National Health Service England (NHSE). *Value in Health* **20**, A730 (2017).

Whitlock GG, Gibbons, DC, Longford N, *et al.* Rapid testing and treatment for sexually transmitted infections improve patient care and yield public health benefits. *Int J STD & AIDS* 29(5):474-482 (Apr 2018). doi:10.1177/0956462417736431

Harding-Esch E, Huntington SE, Harvey MJ, *et al.* Cost-effectiveness of antimicrobial resistance point-of-care testing for optimising the treatment of gonorrhoea. *Sex Transm Infect* **93**, A34–A35 (2017).

Harding-Esch E, Huntington SE, Burns RM, *et al.* Evaluating the costs, benefits and cost-effectiveness of multi-pathogen point-of-care tests for sexually transmitted infections in symptomatic genitourinary medicine clinic attendees. *Sex Transm Infect* **93**, A205–A205 (2017).

Turner KM, Christensen H, Adams EJ, *et al.* Analysis of the potential for point-of-care test to enable individualised treatment of infections caused by antimicrobial-resistant and susceptible strains of *Neisseria Gonorrhoeae*: a modelling study. *BMJ Open* **7**, e015447 (2017).

Bustinduy AL, Jeyaratnam D, Douthwaite S, *et al.* Point-of-care tests for infectious diseases: barriers to implementation across three London teaching hospitals. *Acta Paediatrica* 106, 1192–1195 (2017).

Vecino Ortiz AI, Glover R & Adams EJ. Modelling the burden of bladder cancer and monitoring cystoscopies in Europe. *European Urology Suppl* **15**, e203 (2016).

Adams EJ. How to prevent cervical cancer: HPV – we are coming to get you! EUROGIN, Salzburg, Austria. (2016).

- Vecino Ortiz AI, Glover RE, Douthwaite ST, *et al.* Estimating the clinical impact and costs of implementing a point of care test for influenza A/B and respiratory syncytial virus on an acute paediatric hospital inpatient ward. Society for Medical Decision Making, London, UK (2016).
- Vecino Ortiz AI, Glover RE, Rabe AJ, *et al.* A rapid influenza test in hospitals could avoid unnecessary paediatric isolation bed days and save cost. Society for Medical Decision Making, London, UK (2016).
- Douthwaite ST, Walker C, Adams EJ, *et al.* Performance of a novel point-of-care molecular assay for the detection of Influenza A, B and Respiratory Syncytial Virus (Enigma® MiniLab™) in children with acute respiratory infection. *J. Clin. Microbiol.* JCM.02887-15 (2015). doi:10.1128/JCM.02887-15
- Adams EJ, Midha D, Postulka A, *et al.* Mapping the diagnostic pathway for breast cancer in England and comparison to Europe. *Value in Health* **18**, A477 (2015).
- Adams EJ, Kendall E, Horner PJ, *et al.* Thinking critically about the value and cost of drugs: an example from managing patients with invasive fungal disease. 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2015), Copenhagen, Denmark (2015).
- Alexander H, Munro-Wild H, Richards P, *et al.* Providing integrated HIV treatment and care for stable patients in general practice. 21st Annual Conference of the British HIV Association, Brighton, UK (2015).
- Adams EJ, Glover R, Vecino Ortiz AI, *et al.* How can European countries improve cervical cancer prevention for women? 30th International Papillomavirus Conference, Lisbon, Portugal (2015).
- Adams, EJ, Glover R, Vecino Ortiz AI, *et al.* Exploring the value of a rapid, on-demand test for the detection of human papillomavirus. 30th International Papillomavirus Conference, Lisbon, Portugal (2015).
- Ceesay MM, Sadique Z, Harris R, *et al.* Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UK. *J Antimicrob Chemother* **70**, 1175–1181 (2015).
- Taylor R, Carlin E, Sadique Z, *et al.* The financial and service implications of splitting fixed-dose antiretroviral drugs – a case study. *Int J STD AIDS* **26**, 75–80 (2015).
- Horner P, Blee K & Adams EJ. Time to manage *Mycoplasma genitalium* as an STI: but not with azithromycin 1g! *Current Opinion in Infectious Diseases* **27**, 68 (2014).BTW
- Price C, Adams EJ & Horner P. Point-of-care testing leads the way. *Parliamentary Review* (2014).
- Adams EJ, Ehrlich A, Turner KM, *et al.* Mapping patient pathways and estimating resource use for point of care versus standard testing and treatment of chlamydia and gonorrhoea in genitourinary medicine clinics in the UK. *BMJ Open* **4**, e005322 (2014).
- Hill C, Nasr R, Fisher MI, *et al.* Estimated cost and payment by results (PBR) tariff reimbursement for idiopathic pulmonary fibrosis services across 14 specialist providers in England. British Thoracic Society Winter Meeting, London, UK (2014).
- Adams E, Ogden D, Ehrlich A, *et al.* Treatment for stable HIV patients in England: can we increase efficiency and improve patient care? *J Health Serv Res Policy* **19**, 131–137 (2014).

Turner KM, Round J, Horner P, *et al.* An early evaluation of clinical and economic costs and benefits of implementing point of care NAAT tests for Chlamydia trachomatis and Neisseria gonorrhoea in genitourinary medicine clinics in England. *Sex Transm Infect* **90**, 104–111 (2014).

Gillespie P, O'Neill C, Adams EJ, *et al.* The cost and cost-effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland. *Sex Transm Infect* **88**, 222–228 (2012).

Turner KM, Adams EJ, Grant A, *et al.* Costs and cost effectiveness of different strategies for chlamydia screening and partner notification: an economic and mathematical modelling study. *BMJ* **342**, c7250 (2011).

Aghaizu A, Adams EJ, Turner KM, *et al.* What is the cost of pelvic inflammatory disease and how much could be prevented by screening for Chlamydia trachomatis? Cost analysis of the prevention of pelvic infection (POPI) trial. *Sex Transm Infect* **87**, 312–317 (2011).